News

An investigational formula of panobinostat called MTX110 may improve outcomes in patients with recurrent glioblastoma.

Pain management specialists were rarely consulted for cancer-related pain, a recent study showed.

Asciminib is a promising agent for frontline chronic myeloid leukemia, Jorge Cortes, MD, explained.

The FDA approved zolbetuximab-clzb plus fluoropyrimidine- and platinum-containing chemotherapy for patients with CLDN18.2-positive locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma.

“Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high-risk myeloma.

The addition of lurbinectedin to atezolizumab improved OS and PFS in patients with extensive-stage small cell lung cancer.

The addition of T4001, an investigation cancer vaccine, to avelumab did not improve progression-free survival vs avelumab alone in cervical and anogenital tumors.

Oncology nurses play a crucial role in monitoring the severity and frequency of treatment-related symptoms, particularly nausea.

An analysis of 16 studies showed that CAR T-cell therapy is safe and effective for relapsed/refractory mantle cell lymphoma.

Testing for ESR1 mutations is essential after ER-positive HER2-negative breast cancer progressed.

The DetermalO identified patients with early-stage triple-negative breast cancer who would benefit from presurgical atezolizumab plus carboplatin and nab-paclitaxel.

The FDA granted namodenoson an orphan drug designation for patients who have pancreatic cancer.

Weekly MR-Linac adaptive radiotherapy limited exposure to normal brain tissue in patients with high-grade glioma.

Adding talazoparib to enzalutamide improved survival in patients with metastatic castration-resistant prostate cancer.

NT-17, a long-acting IL-7 agent, enhances CAR T-cell factors associated with efficacy in patients with relapsed/refractory DLBCL when administered 21 days post-CAR T infusion.

Inavolisib plus palbociclib and fulvestrant was approved for the treatment of PIK3CA-mutant, HR-positive, HER2-negative locally advanced or metastatic breast cancer.

The staging of small cell lung cancer significantly impacts treatment plans and potential side effects.

A supplemental biologics license application was submitted for telisotuzumab vedotin for the treatment of metastatic EGFR wild-type nonsquamous non–small cell lung cancer.

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert explained.

Pelvic transposition may improve quality of life and preserve fertility in patients with gynecologic cancer undergoing pelvic radiation.

A nurse practitioner discussed considerations for managing aromatase inhibitor-related joint pain in patients with breast cancer.

The World Health Organization updated their guidelines to include CINtec PLUS Cytology for gynecologic cancer prevention.

As biomarkers continue to be explored in resectable melanoma, oncology nurses will play a crucial role in the clinical trial process.

An expert explained the role oncology nurses and advanced practice providers play in caring for patients with sarcoma during treatment.

The addition of nivolumab to radiotherapy significantly improved freedom from biochemical recurrence in patients with high-grade prostate cancer.

P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Oral drugs in the HR-positive, HER2-negative metastatic breast cancer space put a focus on clear patient-provider communication about adherence and adverse events.